Background: Aminoglycoside-induced ototoxicity has been reported in neonates but its
incidence is poorly defined, whereas vancomycin-induced ototoxicity has not been reported …

Objectives To assess the extended interval regimen gentamicin associated ototoxicity in
neonatal intensive care unit using hearing tests. Methods Two hundred and twenty neonates …

Study Objective. To characterize the extent that serum gentamicin concentrations are
associated with hearing loss indicated by otoacoustic emission (OAE) screen failure in …

Objective To characterize the association between gentamicin dosing, duration of treatment,
and ototoxicity in hospitalized infants. Study design This retrospective cohort study …

Objective Hearing loss rates in infants admitted to neonatal intensive care units (NICU) run
at 2–15%, compared to 0.3% in full-term births. The etiology of this difference remains poorly …

Background Vancomycin is an extensively used anti-infective drug in neonatal ICUs.
However, exposure–toxicity relationships have not been clearly defined. Objectives To …

Objectives Hearing loss in neonatal intensive care unit (NICU) graduates range from 2% to
15% compared to 0.3% in full-term births, and the etiology of this discrepancy remains …

Context Aminoglycosides, as potent bactericidal antibiotics against aerobic gram-negative
infections, is still widely used, especially in NICU patients, despite their known potential …

Objective To investigate the chance of detecting hearing loss with neonatal hearing
screening in relation to exposure to tobramycin and vancomycin. Study design Automated …

Objective: To understand how aminoglycosides such as gentamicin are used in a tertiary
care setting. To familiarize otologists with the demographics and risk factors associated with …